Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

Oncologist · 2026 · PMC13000110 · PMID 41701175

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

did not reach statistical significanceP = .079so close (0.05 < p ≤ 0.1)

Both PFS and OS tended to be longer in patients with high TMB, although the differences did not reach statistical significance (median PFS: 5.3 vs 1.8 months; HR = 0.51, 95% CI: 0.24-1.08; P = .079; median OS: 55.3 vs 11.1 months; HR = 0.49, 95% CI: 0.22-1.09; P = .079; Figure 2E and F ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.